The U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation to EB-101,  Abeona Therapeutics’ treatment for the inherited skin disease epidermolysis bullosa, or EB. Importantly, the designation also covers a severe form of the blistering and open-wound disorder known as recessive dystrophic epidermolysis bullosa, or RDEB. The FDA…
News
Recent Posts
- Health Canada grants priority review to Filsuvez for EB wound care
- 17 years later, I’m still learning how to navigate EB — and parenthood
- People with RDEB note disease impact, but report better life quality with age
- Living with EB, I’ve learned to adapt and prepare for tough days
- Oral health problems linked to lower quality of life in EB children: Study